Stroke Care First week
|
|
|
- Ross Shepherd
- 10 years ago
- Views:
Transcription
1 Stroke Care First week
2 Florence Nightingale ( )
3 Stroke Unit Dedicated personnel trained in stroke management Stepwise guidelines supported by explicit checklists Continuous monitoring available Stepwise guidelines for diagnosis and treatment Early care and rehabilitation by multidisciplinary team
4 Acute Stroke Unit: Functions (1) Management and monitoring (as described for ER) Confirmation of diagnosis and aetiology using stepwise approach Therapy as appropriate experimental treatments Prevention of early recurrence/progression of stroke Prevention of complications
5 Acute Stroke Unit: Functions (2) Reassurance and support for patient and family Assessment of risk factors for recurrence Immediate start of early rehabilitation Secondary prevention Routine follow-up at outpatient clinics Data bases for research
6 Acute Stroke Unit: Multidisciplinary Team Neurologist, on site neurosurgeon, on duty neuropsychiatrist, on call Internist/cardiologist Specialist nurses Physiotherapists Speech and occupational therapists Neuropsychologists Social workers Other consultants as required
7 First day post stroke NB list Clear airway Adequate oxygenation Swallowing ability Hydration Urinary incontinence Fever avoid/treat and investigate Prevent: DVT, pressure sores, aspiration and trauma
8 First day post stroke NB list Concomitant disease Review home medication Protection of a flaccid shoulder/positioning Information FROM patient and family TO PATIENT FAMILY
9
10 Acute Stroke Unit Functions And Facilities Management throughout the first three weeks...
11
12 Stroke morbidity
13
14 Stroke Units - Patterns of Death
15 Outcomes after stroke unit care
16
17 Stroke Treatment Year 2000 and Beyond Secondary prevention Full recovery Stroke onset Call emergency services Activated (15 minutes) Drugs administered stroke-treatment cocktail Brain scan Neuroprotective drug infused during transport ER stroke team
18
19
20
21
22 Florence Nightingale ( )
23 Secondary Prevention Antiplatelet agents Aspirin -Antiplatelet Trialists Collaboration -25% RR for Stroke -Dose mg Combination Aspirin and Extended Release Dipyridamole -Better than Aspirin (ESPS-2) -23% RR over Aspirin for stroke Clopidogrel (CAPRIE) -8% RR over Aspirin for stroke -Cost / Safer than Ticlopidine Ticlopidine (TASS) -21% RR over Aspirin for stroke -Side effects
24 New vs. Old
25 Anticoagulation Warfarin (Cardiogenic Embolism) Atrial Fibrillation Warfarin with INR % risk reduction Only reason NOT to use Warfarin is an absolute contraindication Aspirin if Warfarin cannot be used Acute MI or LV Thrombus Cardiomyopathy
26 Bloodpressure Straight line relationship between level of BP and stroke risk Post-Stroke Hypertension 7 RCT s pt s with stroke, TIA or ICH Followed for 2 5 years Clear risk reduction of recurrent stroke, MI and vascular events related to degree of BP lowering HOPE 24% stroke, MI and death PROGRESS 43% in recurrent stroke (Both HT and non HT pt s)
27 Bloodpressure AHA Guidelines 2006 All patients with stroke/tia need to be on anti hypertensive treatment Both hypertensive and non hypertensive stroke survivors should be treated ( 10 / 5 ; < 120/80) Lifestyle modifications
28 Carotid Endarterectomy Stroke/TIA with ipsilateral Carotid Stenosis 70% SURGERY advised MUST be done in 2 weeks If surgery cannot be done consider CAS
29 Cholesterol lowering Patients with stroke/tia with Elevated cholesterol Comorbid coronary artery disease Evidence of atherosclerosis Manage according to NCEP III guidelines includes statins; LDL-C < 2.6mmol/L
30 Diabetes Patients with stroke/tia Treat BP to <135/85 Usually combination therapy ACEI or ARB have shown clear decreased renal disease progression Glucose control prevents microvascular complications HbA1C 7%
31 Florence Nightingale ( )
32 Brain Attack The 4.5 Golden Hours
33 EUSI : Goal in Acute Management To improve stroke outcome through improved early management, emergency treatment and acute intervention
34
35 Thrombolysis Status 2007 Meta analysis of all thrombolytic Rx in 3h s Prim. Outcome CONTROL GP = 68.3% Prim. Outcome TREATMENT = 55.2% ARR = 13.1%p= THUS NNT = 7.7 SITS MOST 6483pt Rx by 31/8/06 Independence = 54.3% Mortality = 11.3% Symptomatic ICH = 1.7%
36 PRIMARY PREVENTION SECONDARY PREVENTION ORGANISATION OF STROKE SERVICES ACUTE CARE COMPREHENSIVE REHABILITATION
37 Florence Nightingale ( )
38 Emergency Medical Services Full partners in acute stroke care Recognition of stroke using simple criteria High priority code for stroke Urgent transport to best-equipped hospital
39 Multidisciplinary Team Prevent complications - through vigilant delivery of care Prevent avoidable disability - through early rehabilitation Prevent recurrence - through appropriate secondary prevention
40 Stroke Unit Essentials Educating Training Level 1 evidence Weekly program Formal education 1-6 days/year Themes: a)team pt s + carers + multidisc. b)early + intensive rehab c)staff with special stroke interest d)active carer involvement
41 Stroke Unit Staff This is true 24 / 7 / 365 service! Educate, educate, educate ENTHUSIASM and KNOWHOW INVEST IN PEOPLE
42 Our Motivation The patient like art, is bigger than we are. He will have the last word. He will outlast us. His pain will be ours, and his terror, and his hopes, and finally, perhaps, his illness. For what are we all, ultimately but patients John H. Stone M.D.
43
44 Florence Nightingale ( )
Secondary Stroke Prevention Luke Bradbury, MD 10/4/14 Fall WAPA Conferfence
Guidelines Secondary Stroke Prevention Luke Bradbury, MD 10/4/14 Fall WAPA Conferfence Stroke/TIA Nearly 700,000 ischemic strokes and 240,000 TIAs every year in the United States Currently, the risk for
Stroke: Major Public Health Burden. Stroke: Major Public Health Burden. Stroke: Major Public Health Burden 5/21/2012
Faculty Prevention Sharon Ewer, RN, BSN, CNRN Stroke Program Coordinator Baptist Health Montgomery, Alabama Satellite Conference and Live Webcast Monday, May 21, 2012 2:00 4:00 p.m. Central Time Produced
AHA/ASA Ischemic Stroke Performance Measures
AHA/ASA Ischemic Stroke Performance Measures 1. Venous thromboembolism prophylaxis Percentage of patients with ischemic stroke who receive venous thromboembolism prophylaxis Numerator Hospital day 0 or
ALBERTA PROVINCIAL STROKE STRATEGY (APSS)
ALBERTA PROVINCIAL STROKE STRATEGY (APSS) Stroke Systems of Care Key Components APSS Pillar Recommendations March 28, 2007 1 The following is a summary of the key components and APSS Pillar recommendations
Medical Management of Ischemic Stroke: An Update. Siddharth Sehgal, MD Medical Director, TMH Neuroscience Center
Medical Management of Ischemic Stroke: An Update Siddharth Sehgal, MD Medical Director, TMH Neuroscience Center Objectives Diagnostic evaluation and management of acute ischemic stroke. Inpatient management
CLINICAL GUIDELINE FOR SECONDARY PREVENTION AFTER STROKE OR TIA (PRIMARY AND SECONDARY CARE CORNWALL) MANAGEMENT 1. Aim/Purpose of this Guideline
CLINICAL GUIDELINE FOR SECONDARY PREVENTION AFTER STROKE OR TIA (PRIMARY AND SECONDARY CARE CORNWALL) MANAGEMENT 1. Aim/Purpose of this Guideline The aim of this document to inform clinicians on management
STROKE PREVENTION IN ATRIAL FIBRILLATION
STROKE PREVENTION IN ATRIAL FIBRILLATION OBJECTIVE: To guide clinicians in the selection of antithrombotic therapy for the secondary prevention of ischemic stroke and arterial thromboembolism in patients
ACCIDENT AND EMERGENCY DEPARTMENT/CARDIOLOGY
Care Pathway Triage category ATRIAL FIBRILLATION PATHWAY ACCIDENT AND EMERGENCY DEPARTMENT/CARDIOLOGY AF/ FLUTTER IS PRIMARY REASON FOR PRESENTATION YES NO ONSET SYMPTOMS OF AF./../ TIME DURATION OF AF
DERBYSHIRE JOINT AREA PRESCRIBING COMMITTEE (JAPC) MANAGEMENT of Atrial Fibrillation (AF)
DERBYSHIRE JOINT AREA PRESCRIBING COMMITTEE (JAPC) MANAGEMENT of Atrial Fibrillation (AF) Key priorities Identification and diagnosis Treatment for persistent AF Treatment for permanent AF Antithrombotic
3/25/14. To Clot or Not What s New In Anticoagulation? Clotting Cascade. Anticoagulant drug targets. Anita Ralstin, MS CNS CNP. Heparin.
To Clot or Not What s New In Anticoagulation? Anita Ralstin, MS CNS CNP 1 Clotting Cascade 2 Anticoagulant drug targets Heparin XI VIII IX V X VII LMWH II Warfarin Fibrin clot 1 Who Needs Anticoagulation
Stroke Prevention and the In-House Model
1 PRE-DISCHARGE PLAN FOR SECONDARY STROKE IN PATIENTS WITH STROKE OR TRANSIENT ISCHEMIC ATTACK By Renee HultzBrown A Masters Project Submitted to the Faculty of the COLLEGE OF NURSING In Partial Fulfillment
Long term anticoagulant therapy in patients with atrial fibrillation at high risk of stroke: a new scenario after RE-LY trial
Long term anticoagulant therapy in patients with atrial fibrillation at high risk of stroke: a new scenario after RE-LY trial Camillo Autore Università di Roma Sapienza II Facoltà di Medicina e Chirurgia
Treating AF: The Newest Recommendations. CardioCase presentation. Ethel s Case. Wayne Warnica, MD, FACC, FACP, FRCPC
Treating AF: The Newest Recommendations Wayne Warnica, MD, FACC, FACP, FRCPC CardioCase presentation Ethel s Case Ethel, 73, presents with rapid heart beating and mild chest discomfort. In the ED, ECG
ADVANCE: a factorial randomised trial of blood pressure lowering and intensive glucose control in 11,140 patients with type 2 diabetes
ADVANCE: a factorial randomised trial of blood pressure lowering and intensive glucose control in 11,140 patients with type 2 diabetes Effects of a fixed combination of the ACE inhibitor, perindopril,
National Sentinel Stroke Audit Phase I (organisational audit) 2006 Phase II (clinical audit) 2006. Report for England, Wales and Northern Ireland
National Sentinel Stroke Audit Phase I (organisational audit) 2006 Phase II (clinical audit) 2006 Report for England, Wales and Northern Ireland Prepared on behalf of the Intercollegiate Stroke Working
None. Dual Antiplatelet Therapy Plus Systemic Anticoagulation: Bleeding Risk and Management. 76 year old male LINGO 1/5/2015
Financial Disclosure Information Dual Antiplatelet Therapy Plus Systemic Anticoagulation: Bleeding Risk and Management Robert D. McBane, M.D. Division of Cardiology Mayo Clinic Rochester Dual Antiplatelet
STROKE PREVENTION IN ATRIAL FIBRILLATION. TARGET AUDIENCE: All Canadian health care professionals. OBJECTIVE: ABBREVIATIONS: BACKGROUND:
STROKE PREVENTION IN ATRIAL FIBRILLATION TARGET AUDIENCE: All Canadian health care professionals. OBJECTIVE: To guide clinicians in the selection of antithrombotic therapy for the secondary prevention
New Anticoagulants and GI bleeding
New Anticoagulants and GI bleeding DR DANNY MYERS MD FRCP(C) CLINICAL ASSISTANT PROFESSOR OF MEDICINE, UBC Conflicts of Interest None I am unbiased in the use of NOAC s vs Warfarin based on risk benefit
PHARMACOLOGICAL Stroke Prevention in Atrial Fibrillation STROKE RISK ASSESSMENT SCORES Vs. BLEEDING RISK ASSESSMENT SCORES.
PHARMACOLOGICAL Stroke Prevention in Atrial Fibrillation STROKE RISK ASSESSMENT SCORES Vs. BLEEDING RISK ASSESSMENT SCORES. Hossam Bahy, MD (1992 2012), 19 tools have been identified 11 stroke scores 1
Cilostazol versus Clopidogrel after Coronary Stenting
Cilostazol versus Clopidogrel after Coronary Stenting Seong-Wook Park, MD, PhD, FACC Division of Cardiology, Asan Medical Center University of Ulsan College of Medicine Seoul, Korea AMC, 2004 Background
Assessment Blueprint for Stroke Medicine. Mini- DOPS MSF SESR CBD TP A R area
Assessment Blueprint for troke Medicine DOP MF ER CBD TP A R 1. ACUTE TROE OBJECTIVE - TO PROVIDE THE TRAINEE WITH THE NOWLEDGE AND ILL TO CONTRIBUTE TO A COMPREHENIVE PECIALIT ERVICE FOR PATIENT WITH
Novel oral anticoagulant (NOAC) for stroke prevention in atrial fibrillation Special situations
Novel oral anticoagulant (NOAC) for stroke prevention in atrial fibrillation Special situations Dardo E. Ferrara MD Cardiac Electrophysiology North Cascade Cardiology PeaceHealth Medical Group Which anticoagulant
Inpatient Anticoagulation Safety. To provide safe and effective anticoagulation therapy through a collaborative approach.
Inpatient Anticoagulation Safety Purpose: Policy: To provide safe and effective anticoagulation therapy through a collaborative approach. Upon the written order of a physician, Heparin, Low Molecular Weight
Anticoagulation Therapy Update
Anticoagulation Therapy Update JUDY R. WALLING, FNP-BC ARRHYTHMIA MANAGEMENT MUSC CARDIOLOGY Outline Who do we anticoagulate? Review classes of Anticoagulants Review examples of Anticoagulants Review CHADS2
HERTFORDSHIRE MEDICINES MANAGEMENT COMMITTEE (HMMC) RIVAROXABAN RECOMMENDED see specific recommendations for licensed indications below
Name: generic (trade) Rivaroxaban (Xarelto ) HERTFORDSHIRE MEDICINES MANAGEMENT COMMITTEE (HMMC) RIVAROXABAN RECOMMENDED see specific recommendations for licensed indications below What it is Indications
THE INTERNET STROKE CENTER PRESENTATIONS AND DISCUSSIONS ON STROKE MANAGEMENT
THE INTERNET STROKE CENTER PRESENTATIONS AND DISCUSSIONS ON STROKE MANAGEMENT Stroke Prevention in Atrial Fibrillation Gregory Albers, M.D. Director Stanford Stroke Center Professor of Neurology and Neurological
The International Agenda for Stroke
1st Global Conference on Healthy Lifestyles and Noncommunicable Diseases Control Moscow, 28-29 April, 2011 The International Agenda for Stroke Marc Fisher MD, University of Massachusetts Editor-in-Chief,
REMINDER: Please ensure all stroke and TIA patients admitted to hospital are designated as "Stroke Service" in Cerner.
ACUTE STROKE CLINICAL PATHWAY QEH/HH PCH KCMH Souris Western Stewart Memorial O'Leary PATIENT ID INCLUSION CRITERIA* All patients admitted to hosptial with a suspected diagnosis of acute ischemic stroke
Atrial Fibrillation, Chronic - Antithrombotic Treatment - OBSOLETE
Atrial Fibrillation, Chronic - Antithrombotic Treatment - OBSOLETE Clinical practice guidelines serve as an educational reference, and do not supersede the clinical judgment of the treating physician with
FOR THE PREVENTION OF ATRIAL FIBRILLATION RELATED STROKE
www.bpac.org.nz keyword: warfarinaspirin FOR THE PREVENTION OF ATRIAL FIBRILLATION RELATED STROKE Key Concepts In atrial fibrillation (AF) warfarin is more effective than aspirin for stroke prevention.
Atrial fibrillation. Quick reference guide. Issue date: June 2006. The management of atrial fibrillation
Quick reference guide Issue date: June 2006 Atrial fibrillation The management of atrial fibrillation Developed by the National Collaborating Centre for Chronic Conditions Contents Contents Patient-centred
9/5/14. Objectives. Atrial Fibrillation (AF)
Novel Anticoagulation for Prevention of Stroke in Patients with Atrial Fibrillation Objectives 1. Review current evidence on use of warfarin in individuals with atrial fibrillation 2. Compare the three
Antiplatelet and Antithrombotic Therapy. Dr Curry Grant Stroke Prevention Clinic Quinte Health Care
Antiplatelet and Antithrombotic Therapy Dr Curry Grant Stroke Prevention Clinic Quinte Health Care Disclosure of Potential for Conflict of Interest Dr. F.C. Grant Atrial Fibrillation FINANCIAL DISCLOSURE:
Acute Myocardial Infarction (the formulary thrombolytic for AMI at AAMC is TNK, please see the TNK monograph in this manual for information)
ANNE ARUNDEL MEDICAL CENTER CRITICAL CARE MEDICATION MANUAL DEPARTMENT OF NURSING AND PHARMACY Guidelines for Use of Intravenous Alteplase (Tissue Plasminogen Activator (t-pa)), Activase in the Treatment
NICE TA 275: Apixaban for the prevention of stroke and systemic embolism in people with non-valvular atrial fibrillation
Service Notification in response to DHSSPS endorsed NICE Technology Appraisals NICE TA 275: Apixaban for the prevention of stroke and systemic embolism in people with non-valvular atrial fibrillation 1
Three new/novel oral anticoagulants (NOAC) have been licensed in Ireland since 2008:
Key Points to consider when prescribing NOACs Introduction Three new/novel oral anticoagulants (NOAC) have been licensed in Ireland since 2008: Dabigatran Etexilate (Pradaxa ) 75mg, 110mg, 150mg. Rivaroxaban
Rx Updates New Guidelines, New Medications What You Need to Know
Rx Updates New Guidelines, New Medications What You Need to Know Maria Pruchnicki, PharmD, BCPS, BCACP, CLS Associate Professor of Clinical Pharmacy OSU College of Pharmacy Background scope and impact
Bayer Pharma AG 13342 Berlin Germany Tel. +49 30 468-1111 www.bayerpharma.com. News Release. Not intended for U.S. and UK Media
News Release Not intended for U.S. and UK Media Bayer Pharma AG 13342 Berlin Germany Tel. +49 30 468-1111 www.bayerpharma.com Bayer Forms Collaboration with Academic and Governmental Institutions for Rivaroxaban
New Treatments for Stroke Prevention in Atrial Fibrillation. John C. Andrefsky, MD, FAHA NEOMED Internal Medicine Review course May 5 th, 2013
New Treatments for Stroke Prevention in Atrial Fibrillation John C. Andrefsky, MD, FAHA NEOMED Internal Medicine Review course May 5 th, 2013 Classification Paroxysmal atrial fibrillation (AF) Last < 7
The author has no disclosures
Mary Bradbury, PharmD, BCPS Clinical Pharmacy Specialist, Cardiac Surgery September 18, 2012 [email protected] This presentation will discuss unlabeled and investigational use of products The author
2.5mg SC daily. INR target 2-3 30 mg SC q 12 hr or 40mg daily. 10 mg PO q day (CrCl 30 ml/min). Avoid if < 30 ml/min. 2.
Anticoagulation dosing at UCDMC (SC=subcutaneously; CI=continuous infusion) Indication Agent Dose Comments Prophylaxis Any or No bleeding risk factors see adult heparin (VTE prophylaxis) IV infusion order
Birmingham, Sandwell and Solihull Cardiac and Stroke Network. Rivaroxaban or warfarin for treatment of Atrial Fibrillation: Position statement
Birmingham, Sandwell and Solihull Cardiac and Stroke Network Rivaroxaban or warfarin for treatment of Atrial Fibrillation: Position statement Introduction This guidance informs prescribers and commissioners
Antiplatelet and Antithrombotics From clinical trials to guidelines
Antiplatelet and Antithrombotics From clinical trials to guidelines Ashraf Reda, MD, FESC Prof and head of Cardiology Dep. Menofiya University Preisedent of EGYBAC Chairman of WGLVR One of the big stories
New Oral Anticoagulants. How safe are they outside the trials?
New Oral Anticoagulants How safe are they outside the trials? Objectives The need for anticoagulant therapy Indications for anticoagulation Traditional anticoagulant therapies Properties of new oral anticoagulants
KIH Cardiac Rehabilitation Program
KIH Cardiac Rehabilitation Program For any further information Contact: +92-51-2870361-3, 2271154 [email protected] What is Cardiac Rehabilitation Cardiac rehabilitation describes all measures used to
Kevin Saunders MD CCFP Rivergrove Medical Clinic Wellness Institute @ SOGH April 17 2013
Kevin Saunders MD CCFP Rivergrove Medical Clinic Wellness Institute @ SOGH April 17 2013 Family physician with Rivergrove Medical Clinic Practice in the north end since 1985 Medical Director of the Wellness
New in Atrial Fibrillation
New in Atrial Fibrillation September 2011 Stroke prevention more options Rhythm Control -drugs - alternatives to drugs; ablation Rate Control - pace + ablate A-FIB Dell Stroke Risk AFib Two Principles
DISCLOSURES RISK ASSESSMENT. Stroke and Heart Disease -Is there a Link Beyond Risk Factors? Daniel Lackland, MD
STROKE AND HEART DISEASE IS THERE A LINK BEYOND RISK FACTORS? D AN IE L T. L AC K L AN D DISCLOSURES Member of NHLBI Risk Assessment Workgroup RISK ASSESSMENT Count major risk factors For patients with
Health Professionals who Support People Living with Dementia
Clinical Access and Redesign Unit Health Professionals who Support People Living with Dementia (in alphabetical order) Health Professional Description Role in care of people with dementia Dieticians and
Service Specification Template Department of Health, updated June 2015
Service Specification Template Department of Health, updated June 2015 Service Specification No. : 2 Service: Commissioner Lead: Provider Lead: Period: Anti-coagulation monitoring Date of Review: 31 st
ACUTE STROKE PATHWAY
ACUTE STROKE PATHWAY THERE IS A NEED FOR STATEWIDE STROKE SYSTEM OF CARE ALL MISSISSIPPIANS SHOULD BE ABLE TO ACCESS NEW PROTOCOLS FOR STROKE TREATMENT JOINT EFFORT WITH EMS, PHYSICIANS, HOSPITALS AND
STROKE PREVENTION AND TREATMENT MARK FISHER, MD PROFESSOR OF NEUROLOGY UC IRVINE
STROKE PREVENTION AND TREATMENT MARK FISHER, MD PROFESSOR OF NEUROLOGY UC IRVINE CASE REPORT: ACUTE STROKE MANAGEMENT 90 YEAR OLD WOMAN, PREVIOUSLY ACTIVE AND INDEPENDENT, CHRONIC ATRIAL FIBRILLATION,
Palpitations & AF. Richard Grocott Mason Consultant Cardiologist THH NHS Foundation Trust & Royal Brompton & Harefield NHS Foundation Trust
Palpitations & AF Richard Grocott Mason Consultant Cardiologist THH NHS Foundation Trust & Royal Brompton & Harefield NHS Foundation Trust Palpitations Frequent symptom Less than 50% associated with arrhythmia
Atrial Fibrillation Peter Santucci, MD Revised May, 2008
Atrial Fibrillation Peter Santucci, MD Revised May, 2008 Atrial fibrillation (AF) is an irregular, disorganized rhythm characterized by a lack of organized mechanical atrial activity. The atrial rate is
New Oral Anticoagulants
New Oral Anticoagulants Tracy Minichiello, MD Associate Professor of Medicine Chief, San FranciscoVA Anticoagulation and Thrombosis Service Ansell, J. Hematology Copyright 2010 American Society of Hematology.
GP workshop. Maria Fitzpatrick Nurse Consultant Kings College Stroke Centre
GP workshop Maria Fitzpatrick Nurse Consultant Kings College Stroke Centre Stroke: the Facts Stroke: the Facts Every 5 minutes someone in the UK has a stroke 1 in 4 men and 1 in 5 women will have a stroke
DVT/PE Management with Rivaroxaban (Xarelto)
DVT/PE Management with Rivaroxaban (Xarelto) Rivaroxaban is FDA approved for the acute treatment of DVT and PE and reduction in risk of recurrence of DVT and PE. FDA approved indications: Non valvular
Diabetic nephropathy is detected clinically by the presence of persistent microalbuminuria or proteinuria.
Kidney Complications Diabetic Nephropathy Diabetic nephropathy is detected clinically by the presence of persistent microalbuminuria or proteinuria. The peak incidence of nephropathy is usually 15-25 years
F A S T. Transient ischaemic attack (TIA)
Stroke Helpline: 0303 3033 100 Website: stroke.org.uk Transient ischaemic attack (TIA) A transient ischaemic attack (TIA) is similar to a stroke, but the symptoms do not last as long. However, it should
S9 Administer thrombolytic treatment in acute ischaemic stroke
S9 Administer thrombolytic treatment in acute ischaemic Screening and initiating treatment, overseeing competency of treatment About this workforce competence This competence is about the emergency administration
ACUTE STROKE REGISTRY (NJASR) VERSION 2.0) (Continued)
New Jersey Department of Health ACUTE STROKE REGISTRY (NJASR) VERSION 2.0 A. DEMOGRAPHIC DATA *Hospital Type (1): 1=Primary 2=Comprehensive 3=Other *Hospital Code (2): *Hospital Transferred From Code (3):
Managing diabetes in the post-guideline world. Dr Helen Snell Nurse Practitioner PhD, FCNA(NZ)
Managing diabetes in the post-guideline world Dr Helen Snell Nurse Practitioner PhD, FCNA(NZ) Overview Pathogenesis of T2DM Aims of treatment The place of glycaemic control Strategies to improve glycaemic
National Stroke Association s Guide to Choosing Stroke Rehabilitation Services
National Stroke Association s Guide to Choosing Stroke Rehabilitation Services Rehabilitation, often referred to as rehab, is an important part of stroke recovery. Through rehab, you: Re-learn basic skills
2016 International Stroke Conference Hot Topics Lori M. Massaro, MSN, CRNP Kari Moore, MSN, AGACNP-BC
2016 International Stroke Conference Hot Topics Lori M. Massaro, MSN, CRNP Kari Moore, MSN, AGACNP-BC Disclosures Lori M. Massaro, MSN,CRNP speakers bureau Genentech Kari Moore, MSN, AGACNP-BC -none 1
Hospital-Based Sub-Acute Stroke Care and Secondary Prevention. Timothy Lukovits,, M.D.
Hospital-Based Sub-Acute Stroke Care and Secondary Prevention Timothy Lukovits,, M.D. Volunteer group members Shalini Bansil,, MD Summit NJ Ji Chong,, MD, NYC, NY Srinath Kadimi,, M.D. Fairfield, CT Steve
Atherosclerosis of the aorta. Artur Evangelista
Atherosclerosis of the aorta Artur Evangelista Atherosclerosis of the aorta Diagnosis Classification Prevalence Risk factors Marker of generalized atherosclerosis Risk of embolism Therapy Diagnosis Atherosclerosis
NHS FORTH VALLEY Rivaroxaban for Stroke Prevention in Atrial Fibrillation
NHS FORTH VALLEY Rivaroxaban for Stroke Prevention in Atrial Fibrillation Date of First Issue 06/06/2012 Approved 06/06/2012 Current Issue Date 29/10/2014 Review Date 29/10/2016 Version 1.4 EQIA Yes 01/06/2012
Dual Antiplatelet Therapy. Stephen Monroe, MD FACC Chattanooga Heart Institute
Dual Antiplatelet Therapy Stephen Monroe, MD FACC Chattanooga Heart Institute Scope of Talk Identify the antiplatelet drugs and their mechanisms of action Review dual antiplatelet therapy in: The medical
Introduction. Background to this event. Raising awareness 09/11/2015
Introduction Primary Care Medicines Governance HSCB Background to this event New class of medicines Availability of training Increasing volume of prescriptions Reports of medication incidents Raising awareness
Appendix C Factors to consider when choosing between anticoagulant options and FAQs
Appendix C Factors to consider when choosing between anticoagulant options and FAQs Choice of anticoagulant for non-valvular* atrial fibrillation: Clinical decision aid Patients should already be screened
Getting smart about dyspnea and life saving drug therapy in ACS patients. Kobi George Kaplan Medical Center Rehovot
Getting smart about dyspnea and life saving drug therapy in ACS patients Kobi George Kaplan Medical Center Rehovot 78 year old female Case description Presented with resting chest pain and dyspnea Co morbidities:
STROKE SERIES SS10. Understanding thrombolysis treatment For stroke
STROKE SERIES SS10 Understanding thrombolysis treatment For stroke Chest Heart & Stroke Scotland improves the quality of life for people in Scotland affected by chest, heart and stroke illness, through
Renovascular Hypertension
Renovascular Hypertension Philip Stockwell, MD Assistant Professor of Medicine (Clinical) Warren Alpert School of Medicine Cardiology for the Primary Care Provider September 28, 201 Renovascular Hypertension
NHS FORTH VALLEY Rivaroxaban for Stroke Prevention in Atrial Fibrillation
NHS FORTH VALLEY Rivaroxaban for Stroke Prevention in Atrial Fibrillation Date of First Issue 06/06/2012 Approved 06/06/2012 Current Issue Date 06/06/2012 Review Date 06/06/2014 Version 1.1 EQIA Yes /
Listen to your heart: Good Cardiovascular Health for Life
Listen to your heart: Good Cardiovascular Health for Life Luis R. Castellanos MD, MPH Assistant Clinical Professor of Medicine University of California San Diego School of Medicine Sulpizio Family Cardiovascular
Cardiac Sources of Stroke. Robert N. Piana, M.D. Professor of Medicine Director, Adult Congenital Interventional Cardiology
Cardiac Sources of Stroke Robert N. Piana, M.D. Professor of Medicine Director, Adult Congenital Interventional Cardiology Stroke Pathophysiology Cardiologists Well Suited to Help 795K CVA per year, 87%
Level III Stroke Center Data Collection Requirements
Who? Level III Stroke Center Data Collection Requirements All LERN Level III Stroke Centers. LERN Level I and II Stroke Centers have reporting requirements to The Joint Commission or other Board approved
A PATIENT S GUIDE TO SECONDARY PREVENTION IN ACUTE CORONARY SYNDROME (ACS)
A PATIENT S GUIDE TO SECONDARY PREVENTION IN ACUTE CORONARY SYNDROME (ACS) This medicine is subject to additional monitoring. This will allow quick identification of new safety information. If you get
TA 256: Rivaroxaban for the prevention of stroke and systemic embolism in people with atrial fibrillation
Service Notification in response to DHSSPS endorsed NICE Technology Appraisals TA 256: Rivaroxaban for the prevention of stroke and systemic embolism in people with atrial fibrillation 1 Name of Commissioning
Evaluating ED Patients with Transient Ischemic Attack: Inpatient vs. Outpatient Strategies
Evaluating ED Patients with Transient Ischemic Attack: Inpatient vs. Outpatient Strategies Michael A. Ross MD FACEP Associate Professor of Emergency Medicine Wayne State University School of Medicine Detroit
Dabigatran etexilate for the treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism ERRATUM
Dabigatran etexilate for the treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism ERRATUM This report was commissioned by the NIHR HTA Programme as project number 12/78
WHY DO MY LEGS HURT? Veins, arteries, and other stuff.
WHY DO MY LEGS HURT? Veins, arteries, and other stuff. Karl A. Illig, MD Professor of Surgery Chief, Division of Vascular Surgery Mitzi Ekers, ARNP April 2013 Why do my legs hurt? CONFLICTS OF INTEREST
Update on Antiplatelets and anticoagulants. Outlines. Antiplatelets and Anticoagulants 1/23/2013. Timir Paul, MD, PhD
Update on Antiplatelets and anticoagulants Timir Paul, MD, PhD Antiplatelets Indications Doses Long term use (beyond 12 months) ASA and combination use of NSAIDS ASA resistance Plavix resistance Plavix
NHS Midlands and East Stroke Services Specification
NHS Midlands and East Stroke Services Specification Version Control Version No. Date Authors/ Editors To be reviewed by Status v1.0 01 June 2012 Tim Lawrence, Laura Dendy External Expert Advisory Group
Protocol for the management of atrial fibrillation in primary care
Protocol for the management of atrial fibrillation in primary care Protocol for the management of atrial fibrillation in primary care Contents Page no Definition 2 Classification of AF 2 3 Identification
NHS DORSET CLINICAL COMMISSIONING GROUP POSITION STATEMENT ON ORAL ANTICOAGULANTS IN ATRIAL FIBRILLATION
Version 3 August 2014 NHS DORSET CLINICAL COMMISSIONING GROUP POSITION STATEMENT ON ORAL ANTICOAGULANTS IN ATRIAL FIBRILLATION Dorset CCG commissions the use of newer oral anti-coagulants in accordance
Appendix L: HQO Year 1 Implementation Priorities
Appendix L: HQO Year 1 Implementation Priorities Chronic Obstructive Pulmonary Disease (Source: COPD Chairs) Non-Invasive Positive Pressure Ventilation Early Ambulation If possible, seek patient preferences
Understanding diabetes Do the recent trials help?
Understanding diabetes Do the recent trials help? Dr Geoffrey Robb Consultant Physician and Diabetologist CMO RGA UK Services and Partnership Assurance AMUS 25 th March 2010 The security of experience.
What is Vascular Surgery Worth to a Health Care System?
What is Vascular Surgery Worth to a Health Care System? Peter Gloviczki, MD Robert Zwolak, MD Sean Roddy, MD Conflict of Interest NONE Mayo Clinic, Rochester, MN, Dartmouth-Hitchcock Medical Center, Lebanon,
When a stroke happens
When a stroke happens When a stroke happens What to expect during the first hours, days and weeks after a stroke We re for life after stroke Introduction Need to talk? Call our confidential Stroke Helpline
Dabigatran: Amber Drug Guidance for the prevention of stroke and systemic embolism in patients with non-valvular AF
Leeds Dabigatran: Amber Drug Guidance for the prevention of stroke and systemic embolism in patients with non-valvular AF Amber Drug Level 3 (amber drug with monitoring requirements) We have started your
DUAL ANTIPLATELET THERAPY. Dr Robert S Mvungi, MD(Dar), Mmed (Wits) FCP(SA), Cert.Cardio(SA) Phy Tanzania Cardiac Society Dar es Salaam Tanzania
DUAL ANTIPLATELET THERAPY Dr Robert S Mvungi, MD(Dar), Mmed (Wits) FCP(SA), Cert.Cardio(SA) Phy Tanzania Cardiac Society Dar es Salaam Tanzania DUAL ANTIPLATELET THERAPY (DAPT) Dual antiplatelet regimen
